TY - JOUR
T1 - Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury
AU - Smirnov, Igor
AU - Walsh, James T.
AU - Kipnis, Jonathan
N1 - Funding Information:
This work was primarily supported by a grant from the National Institute on Aging, NIH (award NS061973 to JK) and in part by a grant from the National Institute of Mental Health , NIH ( MH096484 to JK).
PY - 2013/7
Y1 - 2013/7
N2 - Copolymer (Cop)-1, also known as glatiramer acetate, is an active compound of Copaxone, a drug widely used by patients with multiple sclerosis (MS). Copaxone functions in MS through two mechanisms of action, namely immunomodulation and neuroprotection. Because the immune system is suppressed or altered in depressed individuals, and since depression is often associated with neurological conditions, we were interested in examining whether the neuroprotective effect of Copaxone persists under conditions of stress-induced depressive behavior. We exposed mice to unpredictable chronic mild stress for 4. weeks and then treated them with three doses of Copaxone at 3-day intervals, with the last dose given immediately before the mice underwent a crush injury to the optic nerve. Whereas nonstressed mice exhibited a strong neuroprotective response after Copaxone treatment, this effect was completely absent in mice that underwent chronic mild stress. Interestingly, when Copaxone was combined with Prozac, the neuroprotective effect of Copaxone was regained, suggesting that chronic mild stress interferes with the neuroprotective effect of Copaxone. These results may shed a light on mechanism of action of Copaxone and lead to new combined therapies for neurodegenerative and neuroinflammatory disorders.
AB - Copolymer (Cop)-1, also known as glatiramer acetate, is an active compound of Copaxone, a drug widely used by patients with multiple sclerosis (MS). Copaxone functions in MS through two mechanisms of action, namely immunomodulation and neuroprotection. Because the immune system is suppressed or altered in depressed individuals, and since depression is often associated with neurological conditions, we were interested in examining whether the neuroprotective effect of Copaxone persists under conditions of stress-induced depressive behavior. We exposed mice to unpredictable chronic mild stress for 4. weeks and then treated them with three doses of Copaxone at 3-day intervals, with the last dose given immediately before the mice underwent a crush injury to the optic nerve. Whereas nonstressed mice exhibited a strong neuroprotective response after Copaxone treatment, this effect was completely absent in mice that underwent chronic mild stress. Interestingly, when Copaxone was combined with Prozac, the neuroprotective effect of Copaxone was regained, suggesting that chronic mild stress interferes with the neuroprotective effect of Copaxone. These results may shed a light on mechanism of action of Copaxone and lead to new combined therapies for neurodegenerative and neuroinflammatory disorders.
KW - CNS injury
KW - Copaxone
KW - Copolymer-1
KW - Fluoxetine (Prozac)
KW - Glatiramer acetate
KW - Neuronal survival
KW - Neuroprotection
KW - Stress
UR - http://www.scopus.com/inward/record.url?scp=84878139938&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2012.12.015
DO - 10.1016/j.bbi.2012.12.015
M3 - Article
C2 - 23295266
AN - SCOPUS:84878139938
SN - 0889-1591
VL - 31
SP - 177
EP - 182
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -